Obsidian Therapeutics, Inc. (OBX)

NASDAQ: OBX · Real-Time Price · USD

13.98

+0.04 (0.29%)

Oct 23, 2026, 4:00 PM EDT - Market closed

Obsidian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	17.91	19.55	18.07
Research & Development	79.32	86.11	73.19
Operating Expenses	97.23	105.67	91.26
Operating Income	-97.23	-105.67	-91.26
Interest & Investment Income	3	5.06	8.15
Pretax Income	-94.22	-100.61	-83.11
Net Income	-94.22	-100.61	-83.11
Net Income to Common	-94.22	-100.61	-83.11
Net Income Growth	-	-	-
Shares Outstanding (Basic)	3	0	0
Shares Outstanding (Diluted)	3	0	0
Shares Change	-	8.46%	-
EPS (Basic)	-31.84	-2057.07	-1843.10
EPS (Diluted)	-31.84	-2057.07	-1843.10
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-91.83	-90.47	-75.78
Free Cash Flow Per Share	-31.03	-1849.72	-1680.59
EBITDA	-95.86	-104.18	-89.73
D&A For EBITDA	1.37	1.48	1.53
EBIT	-97.23	-105.67	-91.26

SEC Filings: 10-K · 10-Q